901-47-3
901-47-3
Chemical Structure
TAME
- CAS No.: 901-47-3
- Formula:C14H22N4O4S
- Molecular Weight:342.41
IUPAC Name: methyl tosyl-L-argininate
InChIKey: FKMJXALNHKIDOD-LBPRGKRZSA-N
SMILES: CC1=CC=C(C=C1)S(N[C@H](C(OC)=O)CCCNC(N)=N)(=O)=O
Biological Activity: TAME is an inhibitor of anaphase-promoting complex/cyclosome (APC/C or APC), which binds to APC/C and prevents its activation by Cdc20 and Cdh1, produces mitotic arrest. TAME is not cell permeable[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TAME | 99.51% | TAME is an inhibitor of anaphase-promoting complex/cyclosome (APC/C or APC), which binds to APC/C and prevents its activation by Cdc20 and Cdh1, produces mitotic arrest. TAME is not cell permeable. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-alpha-Tosyl-L-lysine chloromethyl ketone hydrochloride | 99.9% | N-alpha-Tosyl-L-lysine chloromethyl ketone (TLCK), a trypsin like protease inhibitor, sensitizes HeLa cells to Fas-mediated cell death. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TAME hydrochloride | 98.14% | TAME hydrochloride is an inhibitor of anaphase-promoting complex/cyclosome (APC/C or APC), which binds to APC/C and prevents its activation by Cdc20 and Cdh1, produces mitotic arrest. TAME hydrochloride is not cell permeable. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethyl tosylcarbamate | 98.87% | Ethyl tosylcarbamate is an intermediate in the synthesis of Gliclazide (G409877). Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-alpha-Tosyl-Lys chloromethyl ketone hydrochloride | N-alpha-Tosyl-Lys chloromethyl ketone hydrochloride (TLCK hydrochloride) is a Serine protease inhibitor with an IC50 of 12.0 μM against Caspase-3, 54.5 μM against Caspase-6, and 19.3 μM against Caspase-7. It inhibits thrombin-induced nuclear translocation of FOXO1. N-alpha-Tosyl-Lys chloromethyl ketone hydrochloride can be used in research related to leukemia and cardiovascular diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolbutamide | 99.69% | Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tolbutamide sodium | Tolbutamide sodium is a potent and orally active antidiabetic agent. Tolbutamide sodium induces apoptosis in a Ca2+ dependent manner in pancreatic β-cells. Tolbutamide sodium has the potential for the research of non-insulin-dependent diabetes mellitus. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tosyl-L-arginine | 98.03% | Tosyl-L-arginine is an arginine derivative. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-2-((tert-Butoxycarbonyl)amino)-5-(3-tosylguanidino)pentanoic acid | (S)-2-((tert-Butoxycarbonyl)amino)-5-(3-tosylguanidino)pentanoic acid is an arginine derivative. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Carbutamide | 99.43% | Carbutamide (BZ-55) is an orally active and first-generation sulfonylurea with hypoglycemic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
((4-(tert-Butyl)phenyl)sulfonyl)methionine | ((4-(tert-Butyl)phenyl)sulfonyl)methionine can be used for peptide synthesis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zeng X, et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 2010 Oct 19;18(4):382-95. [Content Brief]
- [2]. Zeng X, et al. An APC/C inhibitor stabilizes cyclin B1 by prematurely terminating ubiquitination. Nat Chem Biol. 2012 Feb 26;8(4):383-92. [Content Brief]
